menu
    • menu
    [{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ Altum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Altum Pharmaceuticals \/ Altum Pharmaceuticals"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Pontificia Universidad Catolica de Chile","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Altum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHILE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alpha-2b","moa":"Interferon-alpha 2 (IFNA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altum Pharmaceuticals \/ Altum Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Altum Pharmaceuticals \/ Altum Pharmaceuticals"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AP-002","moa":"RANKL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Altum Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Altum Pharmaceuticals

    Menu

    Altum Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Pontificia Universidad Catolica de Chile

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile

                            Details : The trial tests BetterLife’s proprietary inhaled interferon alpha-2b product, AP-003 administered via nebulizer. AP-003, being a Type I interferon, is a broad acting antiviral agent used in COVID-19 patients.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Pontificia Universidad Catolica de Chile

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alpha-2b

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Pontificia Universidad Catolica de Chile

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

                            Details : Interferon Alpha-2b is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : Interferon Alpha-2b

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Pontificia Universidad Catolica de Chile

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : BetterLife Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universid...

                            Details : The IFN-a2b treatment arms will receive BetterLife’s proprietary inhaled IFN-a2b product, AP-003, administered via nebulizer, twice daily for 10 days.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 27, 2021

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : BetterLife Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP...

                            Details : Altum Pharmaceuticals has entered into a Letter of Intent with Pontificia Universidad Católica de Chile to conduct a randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients testing Altum’s proprietary inhaled interferon alpha-2b prod...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 11, 2021

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Cli...

                            Details : Altum reports that in May 2020 management requested a pre-IND meeting with the FDA with the intent to discuss the planned development of AP-003 (Interferon Alpha-2b for inhalation) for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            July 27, 2020

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum

                            Details : BetterLife has amended terms of the agreement entered into on May 6, 2020 with Altum to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AP-003, a potential COVID-19 treatment.

                            Product Name : AntiCovir

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 11, 2020

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum

                            Details : BetterLife has secured lock-up agreements from shareholders of Altum Pharmaceuticals Inc. representing 67.12% of the outstanding common shares of Altum. BetterLife and Altum entered collaboration to to commercialize and sell AP-003 for COVID-19.

                            Product Name : AntiCovir

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 04, 2020

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : $20.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BetterLife Pharma Enters into a Licensing Agreement with Altum Pharmaceuticals

                            Details : BetterLife Pharma has been worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a COVID-19 treatment, from Altum Pharmaceuticals Inc.

                            Product Name : AntiCovir

                            Product Type : Protein

                            Upfront Cash : $5.0 million

                            May 07, 2020

                            Lead Product(s) : AP-003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BetterLife Pharma

                            Deal Size : $20.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altum Pharmaceuticals

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of AP-002 in Patients With Solid Tumors

                            Details : AP-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 29, 2019

                            Lead Product(s) : AP-002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth